Hence, it can be postulated that RGS1 is a myeloma driver gene that exerts its oncogenic activity via suppressing p38α mediated antagonism of the GRAP2/JNK-cJun pathway (Fig. 6h). This evidence concerns the gene JUN and plasma cell myeloma.